Geron Corporation (GERN) Stock Analysis

Q: What is the GERN stock price target?

Take-profit $2.96 (+142.6% upside). Target $2.96 (+138.7%), stop $1.16 (−6.9%), A.R:R 9.6:1.

Q: What are the risks of investing in GERN?

Market cap $0.79B below $1B minimum; Market cap $0.79B below $1B minimum; Momentum score 2.2/10 — below 4.5 minimum.

Q: Is GERN overvalued or undervalued?

Geron Corporation trades at a P/E of N/A (forward 18.9). TrendMatrix value score: 8.2/10. Overall verdict: Hold.

Q: What do analysts say about GERN?

13 analysts cover GERN with a consensus score of 3.9/5. Average price target: $3.

HoldModerate ConfidenceUpdated 16 hr ago (May 20, 2026, 1:36 AM ET)

Healthcare · Biotechnology

Hold if already holding. Not a fresh buy at $1.24, but acceptable to hold if already in. Reason: Market cap $0.79B below $1B minimum.

$1.24+142.6% A.UpsideScore 6.0/10#24 of 157 Biotechnology

QualityF-score6 / 9FCF yield-11.68%

Stop $1.16Target $2.96(analyst − 13%)A.R:R 9.6:1

Analyst target$3.40+174.2%5 analysts

$2.96our TP

$1.24price

$3.40mean

Hold if already holding. Not a fresh buy at $1.24, but acceptable to hold if already in. Reason: Market cap $0.79B below $1B minimum. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Market cap $0.79B below $1B minimum. Not in investable universe. Score 6.0/10, moderate confidence.

Passes 7/8 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 78d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: aggressive.

Recent Developments — Geron Corporation

Latest news

Geron To Present Real-World Moffitt Cancer Center Study Showing RYTELO (imetelstat) Safety And Efficacy In Lower-Risk MD — benzinga May 12, 2026
Earnings Scheduled For May 6, 2026 — benzinga May 6, 2026
Geron Reports Q1 2026 Results: Full Earnings Call Transcript — benzinga May 6, 2026 neutral
Geron Expects FY26 RYTELO Net Product Revenue $220M-$240M; Sees Total Operating Expenses $230M-$240M — benzinga May 6, 2026 neutral
Geron Q1 EPS $(0.01) Beats $(0.02) Estimate, Sales $51.771M Beat $50.582M Estimate — benzinga May 6, 2026 positive

Generated 2026-05-20T21:06:21Z.

Thesis

Rewards

No bull case signals

Risks

Market cap $0.79B below $1B minimum

Key Metrics

P/E (TTM)—

P/E (Fwd)18.9

Mkt Cap$789M

EV/EBITDA-17.3

Profit Mgn-34.3%

ROE-27.1%

Rev Growth30.9%

Beta0.68

DividendNone

Rating analysts13

Quality Signals

Piotroski F6/9MoatNarrow

Options Flow

P/C3.25bearish

IV211%elevated

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer

Rating Breakdown

2 floor-breakers·1 ceiling hit

Overall = weighted sum of the 10 dimension scores. Fundamentals (Value/Quality/Growth) carry 45%; market signals (Momentum/Sentiment/Insider/Peer) carry 40%; structure (Technical/Risk/Catalyst) carries 15%.

DimensionScoreWeightContribution

Value8.215%1.23

Quality3.115%0.46

Growth10.015%1.50

Momentum2.210%0.22

Sentiment7.210%0.72

Insider Activity5.010%0.50

Peer Rank4.410%0.44

Technical Setup7.25%0.36

Risk Profile3.95%0.20

Catalyst7.55%0.38

Overall (Σ contributions)6.01

Small float-rounding may cause last-digit differences between this sum and the displayed Overall.

Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static

Obv

1.0

Volume

1.2

Ma Position

2.2

Rsi

3.0

Macd

3.4

Capitulation risk (RSI 27, below 200MA)Volume distribution (falling OBV)Below 200-MA but MA still rising (+2.2%/30d) — pullback in uptrend, not confirmed weakness

Clinical-stage biotech: losses expected pre-commercialisation. Quality floor doesn't distinguish R&D investment from operational decay — components above tell the real story.static

Roe

0.0

Roa

0.0

Operating Margin

0.0

Net Margin

0.0

Fcf Quality

0.0

Rule Of 40

3.0

Current Ratio

6.2

Moat

6.5

Piotroski F

6.7

Gross Margin

9.0

Cash-burning: FCF -47% of revenueRule of 40: -16 (fail)

GatesMomentum 2.2<4.5A.R:R 9.6 ≥ 1.5Insider activity: OKNo SEC red flagsNEWS EVENTS NONE RECENTEARNINGS PROXIMITY 78d clearSEMI CYCLE PEAK CLEARMATERIALS CYCLE PEAK CLEARSuitability: Aggressive

RSI

27 · Oversold

↓ 20D MA↓ 50D MA↓ 200D MAGOLDEN CROSSSupport $1.20Resistance $1.73

Price Targets

A.Upside+138.7%

A.R:R9.6:1

Position Sizing

ConvictionNone

Suggested %0.5%

Max %1%

RegimeSteady

Risk Alerts

! Market cap $0.79B below $1B minimum

! Momentum score 2.2/10 — below 4.5 minimum

Earnings

3/4 beats

Next Earnings2026-08-05 (78d)

Verdict History

reverse chrono — latest first

Loading history...

Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.

Frequently Asked Questions

Is GERN stock a buy right now?

Hold if already holding. Not a fresh buy at $1.24, but acceptable to hold if already in. Reason: Market cap $0.79B below $1B minimum. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Market cap $0.79B below $1B minimum. Not in investable universe. Target $2.96 (+138.7%), stop $1.16 (−6.9%), A.R:R 9.6:1. Score 6.0/10, moderate confidence.

What is the GERN stock price target?

Take-profit target: $2.96 (+142.6% upside). Target $2.96 (+138.7%), stop $1.16 (−6.9%), A.R:R 9.6:1. Stop-loss: $1.16.

What are the risks of investing in GERN?

Market cap $0.79B below $1B minimum.

Is GERN overvalued or undervalued?

Geron Corporation trades at a P/E of N/A (forward 18.9). TrendMatrix value score: 8.2/10. Verdict: Hold.

What do analysts say about GERN?

13 analysts cover GERN with a consensus score of 3.9/5. Average price target: $3.

What does Geron Corporation do?Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products...

Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. The company's product pipeline includes RYTELO, a telomerase inhibitor for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia; IMerge which is in Phase 3 clinical trial for the treatment of lower-risk myelodysplastic syndromes; IMpactMF that is in Phase 3 for the treatment of relapsed/refractory myelofibrosis; Impress which is in Phase 2 clinical trial to treat higher risk myelodysplastic syndromes and acute myeloid leukemia (AML); IMproveMF which is in Phase 1 clinical trial for the treatment of frontline myelofibrosis; and IMAGINE which is in phase 1/2 clinical trial for the treatment of relapsed/refractory AML. Geron Corporation was incorporated in 1990 and is headquartered in Foster City, California.